Current Neuro-Oncology

Volume 28 Number 4
10 February 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 4, 10 February

Yamamoto Y, Teshigawara A, Tamura R, Takei J, Morimoto Y, Tomoto K, Akasaki Y, Hasegawa Y, Murayama Y, Miyake K, Sasaki H, Tanaka T.
Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.
Cancers (Basel). 2026 Feb 1;18(3):488. doi: 10.3390/cancers18030488. PMID: 41681960. Observational study. ˍ

Li Y, Liu M, Zhang D, Zhao X, Liang C, Wang Y, Wu K, Zhao Z, Ding Z, Gai Q, Fan T.
Pediatric intramedullary spinal tumors: Pathological and clinical outcomes in a 96-case single-institution cohort study.
Neurol Sci. 2026 Feb 2;47(2):221. doi: 10.1007/s10072-026-08831-w. PMID: 41622362. Observational study˰ ˍ

Poon CC, Hagen KM, Sarkar S, Mirzaei R, Silva C, Ueno A, de Robles P, Roldan-Urgoiti G, Yong VW.
Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma.
Neurol Neuroimmunol Neuroinflamm. 2026 Feb 3;13(2):e200530. doi: 10.1212/NXI.0000000000200530. PMID: 41632924. Interventional study. ˍ

Ishikawa M, Hama Y, Tate E, Uematsu M, Takahashi M, Naritaka H, Kusaka G.
Repeated salvage high precision radiotherapy for repeated recurrence of high-grade glioma.
Neurochirurgie. 2026 Feb 4;72(2):101784. doi: 10.1016/j.neuchi.2026.101784. PMID: 41651407. Observational study˰ ˍ

Mathen P, Krauze AV, Rowe L, Chaudhry H, Mackey M, Cooley-Zgela T, Huang E, Shankavaram U, Zalewski C, Snow J, Quezado M, Wu J, Smart D, Camphausen K.
A Phase 1 Dose-Escalation Trial of Reirradiation for Patients With Recurrent Glioblastoma.
Pract Radiat Oncol. 2026 Feb 4:S1879-8500(26)00014-7. doi: 10.1016/j.prro.2025.12.015. PMID: 41651156. Interventional study. ˍ

Shah KH, Khalafallah AM, Knott MV, Himic V, Chandar JS, Govindarajan V, Lu VM, Ivan ME, Komotar RJ, Shah AH.
The Safety and Efficacy of Laser Interstitial Thermal Therapy for Newly Diagnosed Deep-Seated Low-Grade Glioma: A Pilot Study Comparing Outcomes With a Surgical Cohort.
Neurosurgery. 2026 Feb 5. doi: 10.1227/neu.0000000000003951. PMID: 41642008. Observational study˰ ˍ

Taskan E, Kirbas OK, Bozkurt BT, Islek Z, Kasapoglu B, Sahin F.
Extracellular vesicles-mediated communication between glioblastoma and astrocytes promotes pro-tumorigenic activation.
Med Oncol. 2026 Feb 5;43(3):138. doi: 10.1007/s12032-025-03216-z. PMID: 41642509. Laboratory investigation˰ ˍ

Chen J, Oberheim Bush NA, Grabowsky JA, Kline C, Kroetz DL, Taylor JW, Villanueva-Meyer J, Molinaro AM, de Groot JF, Butowski NA, Tedesco M, Rabbitt J, Phillips JJ, Hervey-Jumper S, Aghi MK, Berger MS, Chang EF, Chang SM, Solomon DA, Clarke JL.
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma.
Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-4080. PMID: 41649856. Interventional study. ˍ

Singh A, Patel S, Gould J, Yaffe N, Li G, Blanpain L, Gendreau J.
Clinical predictors of overall survival in pediatric patients with intramedullary spinal tumors: an analysis of the SEER database.
Childs Nerv Syst. 2026 Feb 7;42(1):63. doi: 10.1007/s00381-026-07158-3. PMID: 41653291. Observational study˰ ˍ

de Jong AM, van der Boog ATJ, Post CCB, Cialdella F, Eekers DBP, Hendrikse J, Kramer MCA, Lagerwaard FJ, van der Meulen M, Philippens MEP, Robe PA, Rozema T, de Vos FYFL, Vos-Westerman J, van der Weide HL, Wester G, Zindler J, Snijders TJ, Verhoeff JJC.
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG).
PLoS One. 2026 Feb 9;21(2):e0342337. doi: 10.1371/journal.pone.0342337. PMID: 41662245. Interventional study protocol. ˍ

Akl CF, Andersen BM, Quintana FJ.
Astrocytes in the glioblastoma tumor microenvironment.
Neuro Oncol. 2025 Nov 1;27(11):2749-2750. doi: 10.1093/neuonc/noaf191. PMID: 41697355. Editorial. ˍ

Zhou WT, Wu T, Lu YF, Du SX, Zhao HG, Ren SK, Zhao C, Tian YJ, Zhao F.
Development of an integrated risk stratification model for metastatic medulloblastoma (M2/3) using clinical, radiologic, and molecular variables.
Neurooncol Adv. 2025 Dec 22;8(1):vdaf265. doi: 10.1093/noajnl/vdaf265. PMID: 41727341. Observational study. ˍ

Shigeeda R, Shibahara I, Orihashi Y, Tanihata Y, Fujitani K, Toyoda M, Hyakutake Y, Handa H, Inukai M, Sato S, Shinoda M, Komai H, Uemasu K, Kiga T, Koizumi H, Yamamoto D, Miyasaka K, Sekiguchi T, Matsumoto C, Kusumi M, Oka H, Hide T, Kumabe T.
Retrograde longitudinal imaging analyses of IDH-wildtype glioblastoma reveal its clinical timeline from radiological birth to death.
Neurooncol Adv. 2026 Jan 2;8(1):vdaf275. doi: 10.1093/noajnl/vdaf275. PMID: 41732237. Observational study. ˍ

Yousefi A, Saraee E, Ghalehtaki R.
Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report.
Case Rep Oncol. 2026 Jan 7;19(1):238-247. doi: 10.1159/000549567. PMID: 41669196. Case report. ˍ